Last reviewed · How we verify
NCT05723523: CI Wizard
A Technology-Driven Intervention to Improve Early Detection and Management of Cognitive Impairment
NA trial testing CI-CDS in Dementia in 3,230 participants. Completed in 30 September 2025.
31 August 2025
Quick facts
| Lead sponsor | HealthPartners Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 3,230 |
| Start date | 23 August 2023 |
| Primary completion | 31 August 2025 |
| Estimated completion | 30 September 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- CI-CDS
Conditions studied
- Dementia — all drugs for Dementia →
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
HealthPartners Institute
Who can join
65 and older, any sex, with Dementia or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Most experts advocate for early detection of cognitive impairment (CI) so that patients and caregivers can be prepared for making difficult decisions and to improve quality of life, but studies show that screening alone isn't sufficient to change clinician actions related to early detection. Using predictive modelling developed with machine learning methods and sophisticated clinical decision support (CDS) tools, it is possible to identify patients at elevated risk for CI and make it much easier for primary care to engage and support patients and caregivers in meaningful care planning. The goal of this study is to implement and evaluate a low-cost, highly scalable CI-CDS system integrated within the electronic health record that has high potential to improve early CI detection and care and translate massive public and private sector investments in health informatics into tangible health benefits for large numbers of people.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Confidence in diagnosing and managing care for cognitive impairment in primary care: a survey comparing barriers by primary care clinician type.
JaKa MM, Rossom RC, Borson S, O'Connor PJ, et al · · 2024 · cited 6× · PMID 39221923 · DOI 10.1093/fampra/cmae043 -
Exposure to clinical decision support and training increases primary care clinician confidence in managing cognitive impairment care but not confidence to diagnose.
JaKa MM, Rossom RC, Crouse B, Crain AL, et al · · 2025 · PMID 41225324 · DOI 10.1186/s12875-025-03053-z -
Design and protocol of a pragmatic clinical trial to improve cognitive impairment detection in primary care.
Crouse B, Rossom RC, Crain AL, O'Connor PJ, et al · · 2025 · PMID 40953636 · DOI 10.1016/j.cct.2025.108080
Verify or expand the search:
- PubMed search for NCT05723523
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dementia
Currently open trials in the same condition.
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT06088810 — The Impact of Music Intervention on Sleep · NA · recruiting
- NCT07482800 — Dementia in Fiction and Clinical Narratives · recruiting
- NCT07392944 — Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Home · NA · recruiting
Other HealthPartners Institute trials
Trials by the same sponsor.
- NCT07127133 — An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzhei · NA · not yet recruiting
- NCT07354919 — Axelopran in Advanced Cancers · Phase 2 · not yet recruiting
- NCT06434038 — Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age · Phase 1 · withdrawn
- NCT06914726 — Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes · NA · enrolling by invitation
- NCT06999330 — TMS in Anxiety-Parkinson's Disease · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05723523 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HealthPartners Institute
- Last refreshed: 4 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05723523.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing